Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Abstract

Generalized bone loss (osteoporosis) and fragility fractures can occur in rheumatic and musculoskeletal diseases including rheumatoid arthritis and spondyloarthritis (SpA; including ankylosing spondylitis and psoriatic arthritis). In addition, rheumatoid arthritis can involve localized, periarticular bone erosion and, in SpA, local (pathological) bone formation can occur. The RANK-RANKL-osteoprotegerin axis and the Wnt-β-catenin signalling pathway (along with its inhibitors sclerostin and Dickkopf 1) have been implicated in inflammatory bone loss and formation, respectively. Targeted therapies including biologic DMARDs and Janus kinase (JAK) inhibitors can stabilize bone turnover and inhibit radiographic joint damage, and potentially also prevent generalized bone loss. Targeted therapies interfere at various points in the mechanisms of local and generalized bone changes in systemic rheumatic diseases, and they effect biomarkers of bone resorption and formation, bone mass and risk of fragility fractures. Studies on the effects of targeted therapies on rates of fragility fracture are scarce. The efficacy of biologic DMARDs for arresting bone formation in axial SpA is debated. Improved understanding of the most relevant therapeutic targets and identification of important targeted therapies could lead to the preservation of bone in inflammatory rheumatic and musculoskeletal diseases.

• Authors: Boglárka Soós, Ágnes Szentpétery, Hennie G Raterman, Willem F Lems, Harjit P Bhattoa, Zoltán Szekanecz
• Journal: Nature reviews. Rheumatology (Nat Rev Rheumatol) Vol. 18 Issue 5 Pg. 249-257 (05 2022) ISSN: 1759-4804 [Electronic] United States
• PMID: 35273387 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. Springer Nature Limited.

Chemical References

• Antirheumatic Agents
• Biological Products
• Janus Kinase Inhibitors

Topics

• Antirheumatic Agents (therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Biological Products (therapeutic use)
• Bone and Bones
• Humans
• Janus Kinase Inhibitors (therapeutic use)
• Spondylarthritis (drug therapy)